Navigation Links
Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual Meeting
Date:5/15/2013

ic pancreatic adenocarcinoma, survival rates are the lowest of any cancer. In 2013, it is estimated that almost 45,000 new cases of pancreatic cancer will be diagnosed. About one-in-78 people in the U.S. will develop the disease, affecting equal numbers of men and women, almost always after the age of 45. Its tendency to spread prior to diagnosis makes it the fourth deadliest cancer with a less than six percent five-year relative survival rate, with more than 38,000 people succumbing to the disease each year.1-2

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the possible benefits and attributes of PEGPH20, the anticipated enrollment of patients and possible outcomes for the referenced Phase 2 clinical trial, the possible method of action of PEGPH20 and the anticipated presentation of data from Halozyme's Phase 1b trial and the development of the HA diagnostic tool and the potenti
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
2. Halozyme to Host Fourth Quarter and 2011 Year-End Financial Results Conference Call
3. Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March
4. Halozyme to Host Second Quarter Financial Results Conference Call
5. Halozyme to Host Fourth Quarter and 2012 Year-End Financial Results Conference Call
6. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
7. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
8. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
11. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... SAN DIEGO, California, and BELLINGHAM, Washington, USA (PRWEB) September ... Levinson and International Year of Light and Light-based ... as winners of top awards from SPIE, the ... in San Diego. Awards were presented to Levinson and ... including the Gold Medal of the Society won by ...
(Date:9/2/2014)... used for detailed studies of what happens on the ... research, among other applications. A group of researchers from ... cell membranes form across a large number of vertical ... the interior of a cell and its surroundings takes ... surface layer that holds the cell together and that ...
(Date:9/2/2014)... 2014  TransCelerate BioPharma Inc. ("TransCelerate") today announced ... protecting personal data in Clinical Study Reports (CSRs) ... The document describes an approach to apply when ... other related clinical trial documents, and is available ... the TransCelerate CSR Redaction approach is to provide ...
(Date:9/2/2014)... , Sept. 2, 2014 Orexigen Therapeutics, Inc. ... U.S. Patent and Trademark Office (PTO) has issued a ... evaluated for weight loss. NB32 is a fixed-dose combination ... U.S. Patent No. 8,815,889 claims methods for treating ... The patent expires in 2024. If NB32 is approved ...
Breaking Biology Technology:Levinson, Dudley Win SPIE Directors’ and President’s Awards 2Levinson, Dudley Win SPIE Directors’ and President’s Awards 3Levinson, Dudley Win SPIE Directors’ and President’s Awards 4Nano-forests to reveal secrets of cells 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4
... Bioinformatics Application. Part of "Project GreenLight" Energy Efficiency Initiative. ... ... 17, 2008 -- Convey Computer Corporation today announced at SC08 ... Convey HC-1, to the University of California, San Diego as ...
... Physicists in the USA and at the London Centre for ... of electrons by more than 5,000 per cent, as reported ... a property called ,spin, and work like tiny magnets which ... The state of the spin can be used to store ...
... University of Central Florida researcher may have found a defense ... third of Europe,s population in the Middle Ages and which ... UCF Professor Henry Daniell and his team have developed a ... plague. Findings of his National Institutes of Health and USDA ...
Cached Biology Technology:Convey Computer™ Corporation Announces First Customer: University of California, San Diego at SC08 Conference 2Convey Computer™ Corporation Announces First Customer: University of California, San Diego at SC08 Conference 3Convey Computer™ Corporation Announces First Customer: University of California, San Diego at SC08 Conference 4Convey Computer™ Corporation Announces First Customer: University of California, San Diego at SC08 Conference 5UCF professor develops vaccine to protect against black plague bioterror attack 2UCF professor develops vaccine to protect against black plague bioterror attack 3
(Date:9/2/2014)... digital distribution of media will have lower carbon ... when file sizes are large. , That,s the ... Journal of Industrial Ecology that looked at ... as PlayStation3. Researchers found that Blu-ray Discs delivered ... than game files downloaded over broadband Internet. For ...
(Date:9/2/2014)... new study that could ultimately lead to many new ... Research Institute (TSRI) have adapted a chemical approach to ... that can treat a form of muscular dystrophy. , ... a disease-causing defect as a catalyst to synthesize a ... Disney.,"Because the treatment is synthesized only in diseased cells, ...
(Date:9/2/2014)... participation of the University of Granada has revealed new ... the Iberian Peninsula around the mid Holocene (around 6.000 ... from the Sahara increased. The data came from a ... in Sierra Nevada (Granada) , This study, published in ... the sedimentation of atmospheric dust from the Sahara, a ...
Breaking Biology News(10 mins):Scripps Florida scientists make diseased cells synthesize their own drug 2Scientists obtain new data on the weather 10,000 years ago from sediments of a lake in Sierra Nevada 2
... , Aug. 19, 2013 /PRNewswire-iReach/ -- Jade Holding Group, LLC dba ... and wellness centers, has just announced that Dr. Paul J. ... August. (Photo: http://photos.prnewswire.com/prnh/20130819/MN65951 ) Dr. ... in 1970 as an undergraduate at the University of Miami in ...
... microorganismshundreds to thousands of species of bacteria collectively called ... healthy existence. The gastrointestinal (GI) tractand the colon in ... of bacterial species. But how do these organisms persist ... flux due to foods and fluids moving through it? ...
... August 19, 2013 A study published today found ... accurate and precise method for quality control of next-generation sequencing ... data yield, thereby increasing efficiency and throughput while lowering cost. ... of Biotechniques . "While real-time PCR has ...
Cached Biology News:Dr. Paul J. Reilly, MD, FAAFP, is Named Strax Rejuvenation's Doctor of the Month for August 2Dr. Paul J. Reilly, MD, FAAFP, is Named Strax Rejuvenation's Doctor of the Month for August 3A home for the microbiome 2A home for the microbiome 3A home for the microbiome 4Droplet Digital™ PCR provides accurate quantification of next-generation sequencing libraries 2
... unique human proteins on a 1x3 ... a cross section of all cellular ... high-quality results. Additional control proteins and ... validity and reproducibility., ,UNIchip protein microarrays ...
... UNIchip AV-400 contains 400 unique ... nitrocellulose-coated glass slide. The proteins, all ... Ontology classification, are arrayed in quadruplicate ... and a specific chip layout guarantee ...
... The Sub-Plates are E.Coli glycerol stocks ... well contains 50 cDNA clones with approximately ... of the a master plate well, the ... 96-well PCR to identify the positive well(s). ...
... The TNT Coupled Reticulocyte Lysate ... eukaryotic in vitro translations: a single-tube, ... Systems greatly simplify the process and ... in vitro translation results. Standard rabbit ...
Biology Products: